Short answer
Trevi Therapeutics, Inc. (TRVI) filed an 8-K current report with the SEC on April 17, 2026 reporting Item 1.01 (Entry into a Material Definitive Agreement), Item 2.02 (Results of Operations and Financial Condition), Item 8.01 (Other Events), Item EX-99.1 (Exhibit EX-99.1). $150.8M gross equity offering from 11.6M shares at $13.00 public price.
Trevi Therapeutics, Inc. 8-K event analysis
AI summary of each reported item and its exhibits
Item 1.01 · Entry into a Material Definitive Agreement
- $150.8M gross equity offering from 11.6M shares at $13.00 public price
- Company receives $12.22 per share, with estimated net proceeds of $141.1M
- Underwriters have a 30-day option for 1.74M additional shares
- Full option exercise would increase estimated net proceeds to $162.4M
- Approximately 13.34M total shares possible, creating dilution for existing shareholders
Item 2.02 · Results of Operations and Financial Condition
- Cash, cash equivalents and marketable securities update as of March 31, 2026
- Liquidity position disclosure relevant to funding runway and potential financing needs
Item 8.01 · Other Events
- Estimated $171.8M cash, equivalents and marketable securities as of March 31, 2026
- Offering proceeds expected to extend funding through 2029, including two planned IPF Phase 3 trials
- First IPF Phase 3 trial targets approximately 300 patients, with topline results expected first half 2028
- Second IPF Phase 3 trial targets approximately 130 patients, with topline results expected second half 2027
- Additional capital required for Haduvio commercialization and regulatory approval in non-IPF ILD and RCC indications
Item EX-99.1 · Exhibit EX-99.1
- $150M gross proceeds from sale of 11.6M shares at $13.00 per share, before offering expenses
- Potential additional 1.74M shares through 30-day underwriter option, increasing dilution if fully exercised
- Proceeds provide non-dilutive-free cash funding for clinical-stage Haduvio development and corporate operations
- Expected closing April 20, 2026, subject to customary conditions
- Equity financing may extend Trevi’s runway but increases outstanding share count and shareholder dilution
Generated from the filing text and exhibits; verify against the original. What 8-K item codes mean
Other Trevi Therapeutics, Inc. 8-K filings
Get the next TRVI 8-K as it lands
Follow TRVI for push alerts, or ask the research agent what this filing means.